ReviewInternational journal of molecular sciences2025
Flagellin as a Versatile Adjuvant Platform: Genetic Fusion Approaches for Next-Generation Vaccines.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Roles of the M2 protein of influenza A virus.Virus genes · 2026Review
- An Engineered HR1-Stem Helix-HR2 Trimeric Platform for Developing Broad-Spectrum Coronavirus Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered PCV2 VLPs for Antigen Delivery: A Platform for Next-Generation Veterinary Vaccines.Transboundary and emerging diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Flagellin is the main structural protein of the bacterial flagellum, responsible for the movement of flagellated bacteria. Flagellin activates Toll-like receptor 5, inducing both innate and adaptive immune reactions, which highlights its potential as a vaccine adjuvant, particularly efficient in case of administration via mucosal routes. Genetic fusion of an antigen to flagellin has been shown to enhance the immune responses against the antigen. The molecular architecture of flagellin provides versatile and robust adjuvant functionality, facilitating the development of diverse vaccination strategies against multiple diseases as recombinant protein-based vaccines demonstrate substantial advantages over conventional live-attenuated and inactivated vaccines in both developmental efficiency and safety profiles. We present a comprehensive overview of vaccine design strategies employing genetic fusion of antigens to flagellin for protection against various infectious diseases. The proven effectiveness of flagellin-based delivery has enabled several vaccine candidates to enter clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.